In this report, we use pooled data from randomized clinical trials to identify demographic-, HIV disease-, and antiretroviral therapy (ART)-related risk factors for weight gain after the initiation of ART, highlighting the multifactorial nature of ART-associated weight gain.
Introduction
Excess weight and obesity are an escalating global health concern, affecting an estimated 600 million adults and contributing to substantial morbidity and mortality through an increased risk of cardiovascular disease, diabetes, chronic kidney disease, non-alcoholic steatohepatitis (NASH), and cancer. An Increasing prevalence of overweight and obesity has also been reported in people with HIV (PWH), among whom initiation of antiretroviral therapy (ART) often leads to weight gain. [1] [2] [3] [4] [5] [6] [7] While this weight gain may be a positive prognostic indicator in PWH who are underweight at the time of ART initiation, 6, 8, 9 among those in normal or overweight categories weight gain may increase the risk of cardiovascular and metabolic diseases. 7, 10, 11 Possible mechanisms for ART-associated weight gain include a return-to-health phenomenon, especially in those with advanced HIV disease, with weight returning to a pre-illness baseline.
The mechanism underlying the return-to-health phenomenon is incompletely understood, but likely results from the alleviation of HIV-associated inflammation and accelerated catabolism. 12 Treatment of HIV may also hasten resolution of opportunistic infections and gastrointestinal dysfunction that could adversely affect appetite and nutrient absorption. Additional factors associated with weight gain among PWH include both demographic and HIV-specific characteristics, with greater weight gain observed in black people, women, and in those with high pre-treatment HIV RNA or low CD4 cell counts. 2, [4] [5] [6] [13] [14] [15] Specific ART regimens or drug classes have also been implicated in weight gain, with integrase strand transfer inhibitors (INSTIs) cited in two randomized studies 15, 16 and several retrospective cohort studies. 2, 17, 18 In order to further explore the demographic-, HIV-, and treatment-related contributors to weight gain, we conducted a pooled analysis of eight randomized comparative clinical trials of initial ART. We also explored whether weight changes were associated with adverse metabolic effects. 
Methods

Study design and participants
Pooled analyses included eight Gilead-sponsored trials of participants initiating ART 2003 ART -2015 that satisfied the selection criteria of phase 3 stage, active-controlled design, enrollment of treatment-naïve participants, and follow-up duration of at least 96 weeks; the trial designs, treatment arms, and dates are provided in Supplementary Table 1 . One additional trial (99-903) was included in individual trial analyses ( Figure 1A and 1B) but was excluded from all pooled analyses due to inadequate frequency of weight monitoring. All participants provided informed consent and trials were undertaken in accordance with the Declaration of Helsinki and approved by central or site-specific review boards or ethics committees.
Procedures
All studies included a baseline visit and follow-up visits every 12 weeks through week 96.
Height was collected at baseline; body weight and body mass index calculation (BMI; weight in kilograms divided by height in meters, squared) were performed at each visit. Analyses included only weights that were obtained while the participant was on randomized therapy.
Laboratory evaluation including CD4 cell count and HIV-1 RNA were performed at each study visit. Serum glucose and lipid measurements were performed after an 8 hour fast. All laboratory evaluations were performed by Covance Laboratories, Indianapolis, IN, USA.
Adverse events (AEs) were reported by the site investigators and were coded using the Medical Dictionary for Regulatory Activities (MedDRA); version varied depending on clinical trial.
Diabetes-related treatment-emergent AEs reported by the study site investigators were identified by querying MedDRA terms found in the "hyperglycemia/new-onset diabetes mellitus (SMQ)" class (Supplementary Table 2 and Supplementary Methods).
Statistical analyses
Statistical testing, multivariate models and linear mixed effect models were performed as described in the Supplemental Methods section. All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA).
Results
Population, demographics, and baseline disease characteristics
In the pooled analyses of eight Phase III trials ( Supplementary Table 1 ), 5680 treatment-naïve participants initiated ART. At ART initiation, median BMI was 24.8 kg/m 2 ; 16.3% were obese (BMI ≥30 kg/m 2 ), 31.4% were overweight (BMI 25-29.9 kg/m 2 ), and 52.2% were normal or underweight. Additional baseline weight and demographic data are summarized in Table 1 , and baseline disease characteristics are summarized in Table 2 .
Baseline weight was higher in the more recent trials, as was baseline CD4 count (Error! Reference source not found.1A). Weight gain occurred in all study arms. The magnitude of weight gain was larger in the more recent trials, and the investigational regimen was consistently associated with more weight gain than the comparator (Error! Reference source not found.1B). The international composition of the trials can be found in Supplementary   Figure 1 .
Weight gain in participants initiating ART
In pooled analyses, the 96-week median weight gain was 2.0 kg (IQR -1.0, 5.8), with the greatest rate of weight gain occurring during the initial 48 weeks ( Figure 1C ). Through 96 weeks, 48.6%, 36.6% and 17.3% of participants had at least 3%, 5%, and 10% weight increase from baseline, respectively. Weight gain was not observed in all participants; 30.2% lost weight.
The proportion of participants in overweight and obese BMI categories increased over time Figure 1D ).
Risk factors for any weight gain in participants initiating ART
Baseline CD4 count had the strongest association with weight gain in multivariate models; participants with a baseline CD4 count of <200/μL gained on average 2.97 kg more than participants with baseline CD4 ≥200/μL (95% CI 2.81-3.13, p <0.001)( Table 3 ). Furthermore, increases in CD4 count and weight over time were closely correlated ( Supplementary Figure 3 ).
Higher baseline HIV RNA (>100,000 c/mL) was associated with a mean 0.96 kg greater weight gain (95% CI 0.84-1.08, p<0.001); participants with symptomatic HIV or AIDS gained 0.51 kg more than those with asymptomatic HIV (95% CI 0.36 -0.65, p<0.001). Participants who did not inject drugs at baseline gained 1.41 kg more than those who did (95% CI 0.97-1.85, p<0.001). Black race was associated with weight gain, with a mean 0.99 kg greater weight gain compared to non-black participants (95% CI 0.87-1.11, p<0.001). Female sex, age <50 years and persons with baseline obesity had smaller but statistically significant correlations with weight gain (Table 3) .
We further explored these findings by using longitudinal models to study the relationship between sex, race, and weight gain. Female participants gained more weight than male participants, and black participants gained significantly more weight than non-black participants ( Figure 2A Table 3 ). Stratification by both sex and race revealed the greatest weight gain among black female participants, followed by black male participants (96week difference between black females and black males 1.12 kg 95% CI 0.25-1.99, p=0.011; Figure 2C and Supplementary Table 3 ).
Association of antiretroviral regimen components with any weight gain
Longitudinal modeling of weight gain and ART third agent class ( Figure 3A and Supplementary Table 4 ). Weight gain was similar between the NNRTI and PI treatment groups. Absolute weight followed a similar trend ( Figure 3B and Supplementary   Table 4 ).
We next assessed the association between weight gain and the specific INSTI used. Table 4 ).
Among participants taking NNRTI-containing regimens, those taking rilpivirine (RPV) gained more weight compared to those taking efavirenz (EFV) (96-week LS mean weight gain: RPV, 3.01 kg [95% CI 2.35-3.68]; EFV, 1.7 kg [95% CI 1.31-2.09]). Absolute weights were similar after an initial rapid increase in participants taking RPV (Figure 3E-F and Supplementary Table   4 ).
Finally, we assessed whether specific NRTIs were differentially associated with weight gain, 
Risk factors for ≥10% weight increase in participants initiating ART
To understand factors associated with more extreme weight gain, we stratified the pooled trial data into individuals who gained ≥10% body weight over 48 weeks (12.8% of participants) versus those who did not. Individuals with ≥10% weight gain were more likely to be female or black, have a lower baseline weight or BMI, have lower baseline CD4 count, and higher baseline HIV-1 RNA ( Table 4 ).
In multivariate regression models ( We assessed the association between the specific third agent drug and ≥10% weight gain ( with increased risk for ≥10% weight gain compared to AZT. TAF was also associated with an increased risk of ≥10% weight gain compared to ABC (OR 1.90, 95% CI 1.25-2.88, p = 0.003) and TDF (OR 1.47, 95% CI 1.14-1.90, p = 0.003).
Metabolic impacts of significant weight increase
Next, we evaluated whether ≥10% weight gain was associated with subsequent changes in fasting glucose or the incidence of treatment-emergent AEs related to diabetes or hyperglycemia. We found no significant difference in fasting glucose change between participants with ≥10% or <10% weight gain (96-week mean fasting glucose change for both groups was 3 mg/dL, 95% CI 1.01-4.99 mg/dL and 2.39-3.61 mg/dL respectively, Supplementary Figure 2A ). The incidence rate of diabetes-/hyperglycemia-related AEs was higher in individuals with ≥10% weight gain versus those without, although this difference was not statistically significant (1.01 per 100 person-years [PY] [95% CI 0.59, 1.74] and 0.67 per 100 PY [95% CI 0.53, 0.85] respectively, p = 0.18). LDL and triglycerides had similar small increases in both groups, whereas HDL had a small but significant increase in participants with <10% weight increase compared to those with ≥10% weight increase (Supplementary Figure   2B -D). Total cholesterol-to-HDL ratio was slightly higher in the ≥10% weight gain group (week 96 median [IQR] 3.7 [2.9, 4.6] vs 3.5 [2.9, 4.4] p = 0.027). Blood pressure data are available for three trials (264-0110, 380-1489, and 380-1490); no clinically significant changes were observed (week 96 weighted mean change from baseline in systolic and diastolic blood pressure are 2.2 and 1.5 mmHg respectively).
Discussion
In our pooled analysis of eight ART-naïve randomized clinical trials ranging from 2003 to 2019, we found that PWH are initiating ART at higher baseline weight and many gain significant amounts of weight during the first two years of therapy. A mix of demographic, HIV diseasespecific, and ART-specific factors were associated with weight increase from baseline and with more extreme (≥10%) weight gain.
Similar to other reports, we observed higher baseline weight in more recent ART-naïve studies, with median baseline BMIs at or near the overweight category. [1] [2] [3] [4] Weight gain was common following ART initiation: about half of participants gained at least 3% body weight with a median weight gain of 2.0 kg over nearly 2 years of follow-up. This degree of weight gain mirrors the obesity trend observed in the NHANES CARDIA study, where the average American aged 20-40 gained nearly one kilogram per year. 19 Accordingly, the distribution of BMI classes in trial participants shifted toward overweight and obese categories by trial conclusion, approaching the distribution seen in recent HIV cohort studies and in the general population (approximately 1/3 overweight, 1/3 obese). 4, 5, [19] [20] [21] We did not observe a clinically significant metabolic impact of weight gain in our trials as measured by fasting glucose and investigator reported AEs, however this analysis is limited by duration of follow-up, a relatively small number of reported AEs, and the absence of more sensitive markers of glucose tolerance.
Black race and female sex were associated with weight gain, consistent with other studies. 2,5- US, 22 and both may be affected by similar factors. These findings are similar to prior studies reporting a concurrence of HIV and obesity risk in the black population 23 , and highlight the need for increased obesity awareness, monitoring and clinical intervention in this high-risk population.
We observed strong associations between weight gain and HIV disease characteristics.
Disease stage, as reflected by low baseline CD4 count, and high baseline HIV RNA correlated with weight gain in our models of any weight gain and ≥10% weight gain, similar to other reports. 2, [4] [5] [6] 15 These findings support a contribution of the return-to-health phenomenon to weight gain in PWH initiating ART. This effect may be desirable in some individuals, but could also contribute to excess weight gain in individuals with early stage HIV disease and those with normal or above-normal BMI.
Our analyses revealed several important associations between weight gain and ART at the class and drug level. Examining the clinical trials individually, we observe greater weight gain in newer investigational regimens relative to the comparator, consistent with the findings reported by others. 2, 24 In our pooled analyses, INSTI-containing regimens were associated with more weight gain than NNRTI or PI-based regimens, with DTG and BIC associated with more weight gain than EVG/c. Among NNRTIs, RPV was associated with more weight gain than EFV.
Among NRTI pairs, TAF/emtricitabine (FTC) was associated with the most weight gain, ABC/lamivudine (3TC) and TDF/FTC with slightly less weight gain, and AZT/3TC with weight stability. These findings are similar to the ADVANCE trial, in which DTG and TAF were associated with treatment-emergent obesity, while TDF/FTC/EFV was associated with treatment-emergent underweight status and a higher rate of treatment discontinuation. 25 Altogether, these findings establish a pattern of more weight gain with newer ART regimens, possibly reflecting better tolerated, easier to take regimens. 26 
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The hypothesis that improved tolerability may contribute to weight gain in PWH initiating ART is supported by clinical trial data comparing the gastrointestinal (GI) tolerability of HIV regimens.
INSTIs such as DTG, BIC, and RAL do not require boosting with cobicistat, which has been associated with nausea and diarrhea. 27 Among NNRTIs, RPV is better tolerated than EFV, and should be taken with food which may result in higher caloric intake. 28 In the case of NRTIs, early trials demonstrated more GI toxicity with AZT compared to newer NRTIs, including ABC and TDF. 29 There is also evidence that TAF may be associated with better GI tolerability than ABC; in a study comparing BIC/FTC/TAF vs. ABC/DTG/3TC, there was a lower incidence of nausea in the TAF-containing arm, a difference not observed in a study comparing BIC with DTG, both with TAF/FTC. [30] [31] If individual agents contribute to weight gain aside from tolerability, the mechanisms by which they do so is not known. For treatment-naïve PWH, some of the association between weight gain and INSTI-containing regimens could be their faster virologic control compared to older regimens. 32 Another explanation for drug-specific effects on weight could be off-target biological interactions. One such example is the observed interaction between DTG and melanocortin 4 receptor (MC4R), a receptor involved in the regulation of caloric intake by modulating leptin signaling in the central nervous system. [33] [34] This finding is intriguing since mutations in MC4R are associated with heritable obesity. 34 This potential mechanism requires further validation, and it remains unknown whether other INSTIs interact similarly.
Evaluating the effect of ART drugs on weight gain is confounded by HIV disease factors such as return-to-health; some of these limitations may be avoided by studying weight changes in preexposure prophylaxis (PrEP) trials. In the iPrEx study comparing TDF/FTC to placebo, the TDF/FTC arm gained less weight than placebo, suggesting TDF/FTC may have a mild weight suppressive effect. 35 In the DISCOVER trial of TDF/FTC vs. TAF/FTC for PrEP, weight gain at week 48 was 1.1 kg in the TAF/FTC arm with no change in the TDF/FTC arm. 36 Finally, in a phase 2 placebo controlled trial of cabotegravir for PrEP, both arms experienced about 1kg of weight gain over 41 weeks, with no significant difference between arms. 37 Together these findings suggest that heathy participants taking TAF or an INSTI likely experience weight gain much like the general population, which contrasts with the weight-suppressive effect of TDF.
There are several limitations to our analyses. We do not have body composition data, so we cannot determine the anatomical distribution of the observed weight gain. However, data from recent studies suggest that ART-associated weight gain is generalized, with increases in subcutaneous fat, visceral fat, and lean mass. 38 Additionally, our assessment of GI tolerability relied solely on investigator-reported AEs, as more detailed and sensitive participant-reported outcome data are only available in more recent trials. [30] [31] Our analyses did not evaluate other potential contributors to weight gain such as psychiatric comorbidities, concomitant medications, diet, physical activity, or smoking. In the included trials, newer third agents were generally coadministered with newer NRTIs, making it challenging to completely disentangle the independent associations of individual agents with weight gain, and thus these associations should be interpreted with some caution. Finally, while we report two-year data, the duration of follow-up may not be long enough to capture longer-term metabolic consequences of weight gain.
Collectively our results suggest that there are demographic-, HIV-and treatment-related contributors to weight gain in PWH. Our findings raise the possibility that modern ART regimens with improved tolerability and potency may lead to weight gain in some PWH, necessitating increased clinical attention to the maintenance of healthy body weight, lifestyle modification, and exercise at ART initiation. [39] [40] Ongoing studies including the analysis of Supplementary Table 3 . * Inquiry regarding race and ethnicity were not permitted at some study sites One participant with missing race and two participants with missing ethnicity were excluded from the race, combination of sex and race, and ethnicity summary. Table 3 
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. Risk factors for any weight gain in individuals initiating ART.
Stepwise model selection was used to identify baseline risk factors associated with weight gain in individuals initiating ART, resulting in the inclusion of the above eight baseline risk factors in the mixed effexts model. Difference, 95% CI, and p values were determined from the mixed effect model including these eight baseline risk factors and visit as fixed effects and participants as a random effect. 160 (22%) 323 (6.5%) Unknown 0 8 (0.2%) * Inquiry regarding race and ethnicity were not permitted at some study sites. For categorical data, p-value was from the CMH test (general association statistic was used for nominal data, row mean scores differ statistic was used for ordinal data). For continuous data, p-value was from the 2-sided Wilcoxon rank sum test.
Table 5. Risk factors for significant (≥10%) weight gain in individuals initiating ART.
Stepwise model selection was used to identify which baseline risk factors were associated with significant (≥10%) weight gain in individuals initiating ART. As a result, CD4, HIV RNA, BMI, Sex, and Race were selected. Odds Ratio and its 95% CI, p-values were from the logistic regression model including baseline categories of CD4, HIV-1 RNA, BMI, Sex, and Race as risk factors; third agent and NRTIs as fixed effects.
